Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bellerophon Therapeutics Inc

Current price
0.053 USD +0.0033 USD (+6.59%)
Last closed 0.055 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 671 569 USD
Yield for 12 month -96.07 %
21.11.2021 - 28.11.2021

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Address: 20 Independence Boulevard, Warren, NJ, United States, 07059

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

+5 640 000 USD

Last Year

+5 640 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures BLPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -11 035 000 USD
Operating Margin TTM -195.76 %
PE Ratio
Return On Assets TTM -78.47 %
PEG Ratio
Return On Equity TTM -165.96 %
Wall Street Target Price 2 USD
Revenue TTM 5 640 000 USD
Book Value 0.3 USD
Revenue Per Share TTM 0.51 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.89 USD
Diluted Eps TTM -0.89 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -164.06 %

Dividend Analytics BLPH

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BLPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 10.02.2020
Dividend Date 10.02.2020

Stock Valuation BLPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 0.1191
Enterprise Value EBITDA 1.3139
Price Book MRQ 0.1804

Financials BLPH

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BLPH

For 52 weeks

0.029 USD 12.58 USD
50 Day MA 0.049 USD
Shares Short Prior Month 197 473
200 Day MA 0.87 USD
Short Ratio 1.26
Shares Short 90 446
Short Percent 0.9 %

Dynamics of changes in the value of assets




402.79 USD Microsoft Corporation -0.45 (-0.11%)
Detailed analytics

ETF funds



11.59 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2031.07 USD Gold +9.2 (+0.46%)
Detailed analytics